Form 4: Veracyte SVP General Counsel Reports Routine Stock Transaction for Tax Obligations

Veracyte, Inc.'s Senior Vice President and General Counsel, Annie McGuire, reported a disposition of 3,505 shares of common stock on June 2, 2025, solely to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Annie McGuire, SVP, General Counsel of Veracyte, Inc. (VCYT), reported a transaction on June 2, 2025.
• The transaction involved the disposition of 3,505 shares of Veracyte common stock at a price of $26.74 per share.
• This disposition was specifically for tax withholding purposes related to the vesting of Restricted Stock Units (RSUs) and does not represent a sale by the reporting person.
• Following this transaction, Ms. McGuire beneficially owns 97,003 shares of Veracyte common stock.
• The RSUs that vested were granted on February 28, 2022 (1,428 units), August 5, 2022 (892 units), March 6, 2023 (1,463 units), and March 6, 2024 (3,117 units).

Sentiment

Score: 5

Explanation: The transaction is a routine tax-related event for RSU vesting and does not indicate any significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The transaction indicates the vesting of Restricted Stock Units (RSUs) for a key executive, which is a standard component of executive compensation and retention.
• The fact that the shares were disposed of solely for tax withholding purposes, rather than a discretionary sale, suggests continued holding intent for the remaining shares.

Negatives

• No direct negatives as this is a routine tax-related transaction and not a discretionary sale by the insider.

Risks

• No new risks are identified or introduced by this specific Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Veracyte, Inc.'s future performance or strategic outlook.

Management Comments

• The filing indicates that the disposition of shares "does not represent a sale by the reporting person," clarifying that the transaction was solely for tax withholding obligations.

Industry Context

This routine insider transaction, specifically for tax withholding related to RSU vesting, is a common occurrence across publicly traded companies, particularly in the biotechnology and diagnostics sector where equity compensation is prevalent. It does not reflect any specific industry trends or competitive shifts.

Comparison to Industry Standards

• The reported transaction is a standard practice for managing tax obligations arising from equity compensation, aligning with common industry practices for executive compensation and RSU vesting across the U.S. public market. No specific comparable companies or projects are relevant for this type of routine filing.

Related Party Transactions

• This filing reports an insider transaction related to executive compensation (RSU vesting and tax withholding), which is a common and disclosed type of transaction involving a related party (an executive). It does not disclose any unusual or non-standard related party dealings.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related transaction and not a discretionary sale. It reflects the ongoing compensation structure for executives.
• Employees: No direct impact on general employees.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• The document does not outline any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Keywords

Veracyte, VCYT, Form 4, insider transaction, stock ownership, Restricted Stock Units, RSU vesting, tax withholding, Annie McGuire, corporate governance